ArticleDiagnostics (Basel, Switzerland)2020
Endoscopic Ultrasonography Diagnosis of Early Pancreatic Cancer.
Article in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Development and Analytical Evaluation of Urine-Based Test for Detection of Pancreatic Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Pancreatic cancer: Future challenges and new perspectives for an early diagnosis.World journal of clinical oncology · 2025Article
- Noninvasive detection of pancreatic ductal adenocarcinoma in high-risk patients using miRNA from urinary extracellular vesicles.Frontiers in oncology · 2025Article
- Mild Dilatation of the Main Pancreatic Duct Is a Risk Factor for Progression to Pancreatic Cancer in High-Risk Individuals.Gastro hep advances · 2025Article
- Potential of Carbohydrate Antigen 19-9 and Serum Apolipoprotein A2-Isoforms in the Diagnosis of Stage 0 and IA Pancreatic Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- A Quest for Survival: A Review of the Early Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present.Biomolecules · 2024Review
- Artificial intelligence as a noninvasive tool for pancreatic cancer prediction and diagnosis.World journal of gastroenterology · 2023Review
- Usefulness of Practitioner-Led Pancreatic Cancer Screening.Diagnostics (Basel, Switzerland) · 2022Article
- Advances in biomarkers and techniques for pancreatic cancer diagnosis.Cancer cell international · 2022Review
- Oxidative Stress Markers Are Associated with a Poor Prognosis in Patients with Pancreatic Cancer.Antioxidants (Basel, Switzerland) · 2022Article
- Clinical Analysis of Early-Stage Pancreatic Cancer and Proposal for a New Diagnostic Algorithm: A Multicenter Observational Study.Diagnostics (Basel, Switzerland) · 2021Article
- Hypoxia-Related Gene FUT11 Promotes Pancreatic Cancer Progression by Maintaining the Stability of PDK1.Frontiers in oncology · 2021Article
- Pancreatic duct imaging during aging.Endoscopic ultrasoundReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis of pancreatic cancer (PC) can improve patients' prognosis. We aimed to investigate the utility of endoscopic ultrasonography (EUS) for the early diagnosis of PC. This study included 64 patients with PC at an early stage treated at Onomichi General Hospital between January 2007 and January 2020. Diagnostic procedures included contrast computed tomography (CT), magnetic resonance cholangiopancreatography, EUS fine-needle aspiration, and endoscopic retrograde cholangiopancreatography (ERCP) for pancreatic juice cytology. The mean age was 71.3 years. In all, 32 patients were stage 0, and 32 were stage I. As for image findings, the main pancreatic duct (MPD) stenosis was detected in several cases, although CT and MRCP seldom detected tumors. EUS had a high detection rate for stage 0 tumor lesions. The median observation period was 3.9 years. In cases with stage 0, the 1 year and 5 year survival rates were 100% and 78.9%, respectively. In cases with stage I, the 1 year and 5 year survival rates were 96.4% and 66.7%, respectively. EUS has the highest sensitivity among all imaging modalities for detecting small pancreatic tumors. Cases with MPD dilation or stenosis, especially with tumors that cannot be identified on CT and MRI, should have EUS performed. In some cases, EUS was not able to detect any tumor lesions, and ERCP-based pancreatic juice cytology should be useful for pathological diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.